Lido Advisors
RLMD icon

Lido Advisors’s Relmada Therapeutics RLMD Stock Holding History

Lido Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.2K Hold
13,905
– – ﹤0.01% 2042
2026
Q1 		$96.8K Hold
13,905
– – ﹤0.01% 1864
2025
Q4 		$27.9K Hold
13,905
– – ﹤0.01% 1908
2025
Q3 		$27.9K Hold
13,905
– – ﹤0.01% 1810
2025
Q2 		$8.35K Hold
13,905
– – ﹤0.01% 1648
2025
Q1 		$3.75K Buy
+13,905
New +$4.61K ﹤0.01% 1505

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lido Advisors's RLMD Position: Q2 2026 in Review

Lido Advisors held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 13,905 shares worth $96.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Lido Advisors first reported a position in RLMD in Q1 2025 and has held it in 6 quarters since. The position peaked at $96.8K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Lido Advisors held 13,905 shares of Relmada Therapeutics worth $96.2K as of Q2 2026.
  • Lido Advisors left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #2042 holding.
  • Lido Advisors first reported a position in Relmada Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Lido Advisors's Relmada Therapeutics position peaked at $96.8K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.